Cerenovus Launches Cereglide 71 Intermediate Catheter for Revascularization in Patients With Acute Ischemic Stroke

February 7, 2024—Cerenovus, Inc., part of Johnson & Johnson MedTech, announced the launch of Cereglide 71 intermediate catheter with TruCourse Technology. The device is indicated for the revascularization of patients who have experienced an acute ischemic stroke.

According to the company, Cereglide 71 is the newest member of its planned Cereglide family of catheters as part of Cerenovus’ Stroke Solutions portfolio. The catheter is designed for direct aspiration and for the delivery of compatible stent retrievers, such as the Embotrap III revascularization device, into the neurovasculature.

“Balancing trackability, support, and aspiration efficacy is crucial in overcoming the challenges of swift clot access during endovascular thrombectomy,” commented Fawaz Al-Mufti, MD, in the company’s announcement. “As the global first user, in initial use, CEREGLIDE 71 Intermediate Catheter does just that. It impressively navigates, accesses occlusion sites, and engages with effectiveness to aspirate clots, rapidly restoring blood flow in the patient's brain—potentially a life-saving intervention.” Dr. Al-Mufti is an interventional neurologist and Director of the Neuroendovascular Surgery Fellowship at Westchester Medical Center/New York Medical College, in Valhalla, New York.

Cerenovus explained in their press release that the Cereglide 71 intermediate catheter is equipped with TruCourse Technology to increase the flexibility of the device and is designed to help physicians with improved navigation and access to clots, even in challenging anatomical conditions.

Additionally, Cereglide 71 intermediate catheter will also be included in the next phase of the Cerenovus EXCELLENT Registry, a real-world registry focused on studying stroke-inducing blood clot removal by mechanical thrombectomy, noted the company.

Cerenovus also reported that the device will use electronic instructions for use, which is part of the company’s ongoing sustainability efforts to help reduce its environmental footprint, lower CO2 emissions caused during shipment, and facilitate a reduction in health care systems’ postconsumer recycling and medical waste disposal.

The Cereglide 71 intermediate catheter is commercially available in the United States.